SHL completes tender offer for Raytel:
This article was originally published in Clinica
SHL Telemedicine has completed its $10.25 per share tender offer for Raytel Medical, a provider of healthcare services, concentrating on patients with cardiovascular disease. Tel Aviv, Israel-based SHL says around 2.3 million of Raytel's nearly three million shares were tendered. The CEO and director of San Mateo, California-based Raytel, Richard Bader, resigned with immediate effect, following his own unsuccessful attempt to buy the company.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.